Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at

Investment analysts at started coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Free Report) in a report issued on Saturday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Thursday, May 9th.

Check Out Our Latest Stock Analysis on CANF

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $2.29 on Friday. Can-Fite BioPharma has a 52-week low of $1.81 and a 52-week high of $3.33. The stock’s 50-day simple moving average is $2.19 and its 200 day simple moving average is $2.13. The stock has a market capitalization of $8.11 million, a price-to-earnings ratio of -1.28 and a beta of 1.58.

Can-Fite BioPharma (NYSE:CANFGet Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. On average, research analysts forecast that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Armistice Capital LLC acquired a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANFFree Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned approximately 4.36% of Can-Fite BioPharma at the end of the most recent reporting period. 21.00% of the stock is owned by institutional investors and hedge funds.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

See Also

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with's FREE daily email newsletter.